OneCell Diagnostics is now 1Cell.Ai
FOSTER CITY, Calif., May 28, 2025 /PRNewswire/ — 1Cell.Ai, a precision oncology company developing advanced cell and molecular profiling platforms, announced the successful
1Cell.Ai at ASCO 2025: Explore Our Latest Research We’re excited to share 19 new posters and abstracts at the 2025
1Cell.Ai at ASCO 2025: Explore Our Latest Research We’re excited to share 19 new posters and abstracts at the 2025
We’re excited to share our latest research on true live single circulating tumor cell (CTC) capture with zero leukocyte contamination,
We’ve contributed over 40+ publications—from ASCO to ESMO—highlighting advances in circulating tumor cells (CTCs), ctDNA, and AI-powered cancer diagnostics. Explore
Advancing the Science of ctDNA and CTC-Based Diagnostics Across Cancer Types We’re proud to be featured in five recent publications
Presented at ESMO Congress 2024 – Barcelona, Spain This abstract highlights how true single-circulating tumor cell (CTC) genomics can identify
AI-powered precision oncology leader to enhance early-stage clinical studies with the introduction of next-generation technology Foster City, CA. & Mumbai,
Collaborating to Shape the Future of Cancer Care At the 2024 Oncology Think Tank Conclave in Delhi, 1Cell.Ai joined top
Expanding Access to Precision Diagnostics in Asia 1Cell.Ai was proud to participate in Medlab Asia 2024, where we showcased our
